The therapeutic use of Deanxit may be relevant in situations involving specific mild to moderate mental disorders characterized by a dual presentation of symptoms. This combination may be considered relevant in clinical settings where patients require supportive management for concurrent mood and tension issues.

---

Support for Dual Symptom Clusters

The medication is generally used for managing symptom clusters of mixed anxiety and depression, where low mood and depressed feelings occur alongside nervous tension and persistent worry. It is considered relevant for easing symptoms that interfere with energy levels, such as asthenia (unexplained weakness), fatigue, and diminished motivation. The medication may be applied in conditions marked by heightened emotional or physiological tension, including neurotic disorders and psychosomatic affections.

---

Symptom-Focused Benefit

This dual action provides support that helps ease the overall symptom load and may assist with maintaining day-to-day comfort and functional stability. The therapeutic benefit is aimed at assisting patients to cope more steadily with challenging episodes and supporting the management of motivation when symptoms become more noticeable.

“The therapeutic approach is centered on managing emotional disorders where symptoms of low mood and anxiety co-occur.”

Quick Fact: Support for Nervous Tension and Low Drive The medication is commonly applied in scenarios where nervous tension and emotional inertia create noticeable interference with daily stability. It may assist with providing supportive relief that helps moderate these distressing manifestations.

Regulatory References

1. Malta Medicines Authority Package Leaflet

Deanxit: Official Population Eligibility

The eligibility profile for Deanxit (Flupentixol/Melitracen) is strictly defined by regulatory authorities and is determined by pre-existing conditions, age, and physiological status.

Populations Prohibited from Use

Use is strictly contraindicated in patients with a known hypersensitivity to the ingredients, those concurrently taking Monoamine Oxidase Inhibitors (MAOIs), or individuals with a history of recent myocardial infarction or specific cardiac rhythm disturbances. Contraindication also applies to patients experiencing circulatory collapse or severe depression requiring hospitalization. The medicine is not recommended for patients with excitement or overactivity.

Age and Reproductive Restrictions

Deanxit is not recommended for use in children and adolescents under 18 years due to insufficient safety and efficacy data. It should not be administered during pregnancy unless the benefits outweigh the risks, and should not be used while breastfeeding. Older adults are eligible but require special caution.

Conditional Use

Use requires caution in patients with advanced hepatic disease, a history of convulsions or epilepsy, glaucoma, urinary retention, or existing hyperthyroidism. Patients with diabetes require dose monitoring and potential adjustment of anti-diabetic therapy, while those with renal impairment can generally receive standard recommended doses.

Interactions with other medicines and products

The official regulatory profile for Deanxit (Flupentixol/Melitracen) is defined by mandatory restrictions and documented alterations in pharmacodynamic effects with co-administered agents.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the risk of severe reactions like Serotonin Syndrome or hypertensive crises. This restriction applies to non-selective MAOIs and selective MAO-A (Moclobemide) and MAO-B (Selegiline) inhibitors.

A mandatory separation period of 14 days is required when switching between Deanxit and non-selective MAOIs. A minimum of one day must elapse when switching from Moclobemide or Selegiline to Deanxit.

---

Documented Pharmacodynamic Interactions

Co-administration with several medicinal product categories results in specific documented outcomes:

• Enhancement of Effects: Deanxit may enhance the sedative effects of Alcohol and other CNS Depressants (e.g., Barbiturates).
• Potentiation: The cardiovascular effects of Sympathomimetic Agents (e.g., Adrenaline, Ephedrine) may be potentiated. The effects of Anticholinergic Agents may also be potentiated, increasing the risk of paralytic ileus or hyperpyrexia.
• Antagonism: Deanxit may counteract the antihypertensive effects of Adrenergic Neurone Blockers (e.g., Guanethidine, Reserpine) and may reduce the effect of Levodopa.
• Lithium co-administration increases the documented risk of neurotoxicity.

How Deanxit Works

The mechanism of action for Deanxit is rooted in a precise dual-component mechanism that targets two distinct systems of central neurotransmission—dopamine/serotonin modulation and norepinephrine/serotonin reuptake inhibition—resulting in balanced physiological modulation.

---

Dual-Action Monoamine Reuptake Inhibition (Melitracen)

This domain addresses how the Melitracen component acts as an inhibitor of the Norepinephrine Transporter ( NET) and Serotonin Transporter ( SERT). By blocking the reabsorption of these neurotransmitters from the synaptic gap, the mechanism immediately increases their functional availability. This surge in signaling supports the potentiation of noradrenergic and serotonergic pathways, which contributes to the drug’s potentiating effect on central arousal.

Low-Dose Receptor and Autoreceptor Modulation (Flupentixol)

The Flupentixol component exerts its influence by acting as an antagonist at specific receptors, including the Serotonin 5-HT 2A and Dopamine D2 receptors. At the low dosage utilized, it is also believed to modulate presynaptic D2 autoreceptors, functionally increasing dopamine release. This direct receptor-level action produces a rapid, immediate reduction in central arousal signaling via receptor blockade.

Synergistic Central Physiological Balance

The combination of the two distinct mechanisms results in mechanistic synergy, where the rapid arousal reduction effect of Flupentixol coordinates with the sustained central potentiation from Melitracen. This approach is designed to promote balanced neurotransmitter homeostasis, resulting in coordinated modulation of central arousal and central activation.

Deanxit, a fixed-dose combination of flupentixol (0.5 mg) and melitracen (10 mg), is administered exclusively via the oral route as a film-coated tablet. The tablets are intended to be swallowed whole with water and should not be chewed. Administration is not dependent on mealtimes, as the tablets can be taken either with or without food.

---

Official Dosing and Frequency Patterns

The standard adult use pattern typically begins with an initial dose of 2 tablets daily, usually divided into one tablet in the morning and one at noon. In situations requiring an increased initial dose, the morning intake may be raised to two tablets, leading to a total daily intake of 3 tablets. The official maximum daily dose is limited to 4 tablets.

Use Over Time and Population Adjustments

Usage is generally determined for a short-term to medium-term duration. Following the initial phase, the regimen transitions to a maintenance dose, which is commonly reduced to a single 1 tablet taken once daily in the morning. If treatment is to be discontinued, the dosage should be tapered off gradually.

Specific usage principles are outlined for certain groups. For older adults (over 65 years), the standard starting dose is lower: 1 tablet in the morning. The combination is not recommended for use in children and adolescents under the age of 18.

Recent Clinical Evidence Overview

Deanxit is a fixed-dose combination (FDC) therapy containing flupentixol (a neuroleptic with anti-anxiety properties at low doses) and melitracen (a tricyclic antidepressant). This FDC is utilized in some countries for the management of mild to moderate anxiety, depression, and apathy, often when accompanied by somatic (physical) symptoms.

Clinical research has historically investigated the combination for its potential to provide a more rapid initial onset of mood stabilization compared to certain other antidepressants. Studies have explored its use both as monotherapy and in combination with other agents, such as selective serotonin reuptake inhibitors (SSRIs), particularly in the initial phase of treatment.

---

Study Findings

Clinical trials have examined the use of flupentixol/melitracen in patients with mood disorders co-occurring with various chronic somatic conditions, including functional dyspepsia, irritable bowel syndrome (IBS), and chronic subjective dizziness (CSD). Findings from certain studies have indicated:

• Mood and Anxiety: Research in patients with anxiety and depression co-occurring with chronic somatic diseases found differences in response rates on anxiety and depression rating scales compared to placebo, particularly within the first two weeks of treatment.
• Chronic Pain: The combination has been studied for conditions such as persistent idiopathic facial pain (PIFP), with some retrospective studies suggesting a high rate of pain relief in responsive patients.
• Functional Somatic Symptoms: Trials have assessed the potential of this FDC to manage symptoms like chronic subjective dizziness and functional dyspepsia, observing score changes in dizziness and gastrointestinal symptom rating scales, alongside reported improvements in quality of life metrics.

---

Safety Considerations from Trials

Safety data collected across various clinical trials documented that common reported adverse events included dry mouth and dizziness. Severe adverse events, such as rare cases of hyponatremia and associated neurological symptoms, have been documented in case reports following administration of the FDC. Clinical trials noted that participants with conditions like severe liver impairment were excluded from the studies.

Common questions about Deanxit (FAQ)

Q: What is the main purpose of Deanxit according to official sources?

According to the official product information, Deanxit is indicated for the treatment of mild to moderate anxiety, depression, and asthenia (a condition characterized by lack of energy or strength). Official indications state that this combination is generally not recommended for cases of severe depression.

Q: Is Deanxit a type of antidepressant or anxiety medication?

Official indications state that Deanxit is intended to treat both anxiety and depression. The two active components work together to provide both anti-depressant and anti-anxiety effects.

Q: How quickly should I expect to feel any effects from Deanxit?

Official sources indicate that some initial symptom relief may begin to appear within the first few weeks of starting the medicine. However, the full benefits of Deanxit may require a longer period of continuous use to become noticeable.

Q: What are the most commonly reported side effects of Deanxit?

Regulatory documents list several common side effects, including dry mouth, constipation, dizziness, tremor, restlessness, insomnia, and fatigue. These effects are generally described as most prominent when the treatment is first started.

Q: Does Deanxit cause weight gain?

Official product information lists increased appetite and resulting weight gain as known undesirable effects of the medicine.

Q: Can Deanxit affect sleep patterns?

Yes, Deanxit can affect sleep. Regulatory documents list both insomnia (difficulty sleeping) and drowsiness or excessive sleepiness as known side effects.

Q: Is it normal to feel a bit restless when first starting Deanxit?

Yes, official documents list restlessness and agitation as common side effects. Patients often experience these symptoms, which are generally most noticeable during the initial phase of treatment.

Q: Does Deanxit interact with commonly used over-the-counter pain relievers?

Regulatory warnings focus on avoiding medications that affect the central nervous system (CNS), general anesthetics, or drugs that prolong the QT interval. Official information suggests reviewing specific potential interactions with a healthcare professional, as the CNS warning may be relevant to some pain relievers.

Q: Can Deanxit be used if a person has high blood pressure?

The product information states that the medicine is contraindicated (must not be used) for individuals with certain heart rhythm disorders or recent heart attack. It should be used with caution in anyone with existing cardiovascular disease.

Q: What should be done if a dose of Deanxit is forgotten?

Official guidance exists for managing a missed dose. It is advised to consult the Patient Information Leaflet or your prescriber for the specific instructions provided for timing the next dose.

Q: Does Deanxit have a risk of dependence or addiction?

Regulatory requirements to gradually taper the dose when stopping are in place to prevent withdrawal symptoms. The term 'addiction' is not typically applied to Deanxit in official documentation.

Q: Can Deanxit be taken with other types of mental health medication?

The official product information states that Deanxit is contraindicated (must not be used) alongside MAOIs (monoamine oxidase inhibitors). Caution is also advised when it is combined with other central nervous system (CNS) depressants or SSRIs.

Q: Are there specific warnings about driving or operating machinery while on Deanxit?

Official warnings advise patients to avoid driving or operating machinery until they are certain how the medicine affects their concentration and alertness. This is due to the potential for dizziness or drowsiness.

Q: What are the official guidelines regarding Deanxit use during pregnancy?

Regulatory documents state that Deanxit is generally not recommended for use during pregnancy. Official information indicates that babies exposed in the third trimester may be at risk of experiencing withdrawal symptoms after birth.

Q: Is Deanxit safe for use while breastfeeding?

Official product information advises that Deanxit should not be used while breastfeeding. This is because small amounts of the medicine's active components may pass into the breast milk.

Q: Does Deanxit have an effect on sexual function?

Yes, official documents list decreased libido (a reduction in sex drive) as an undesirable effect of the medicine.

Q: Can people with liver or kidney issues use Deanxit?

The product information indicates that the medicine requires caution in patients with advanced hepatic (liver) disease or kidney issues. These conditions typically require closer monitoring during treatment.

Q: What does the research say about Deanxit's effectiveness for general anxiety?

Deanxit is officially indicated for the treatment of anxiety and depression, which signifies that its effectiveness for these conditions has been established in the required regulatory submissions and supporting studies.

Q: Is Deanxit the same as a benzodiazepine?

No, Deanxit is structurally and functionally different from benzodiazepines. Deanxit is a combination of an antidepressant (melitracen) and an antipsychotic (flupentixol), whereas benzodiazepines act on the brain's GABA receptors.

Q: Does Deanxit cause drowsiness or sedation?

Yes, drowsiness or sedation is listed in the official product information as a common side effect, especially when a patient first starts taking the medicine.

Q: Can Deanxit interact with alcohol?

Official product information advises that alcohol should be avoided while taking Deanxit. This is because the medicine may enhance the sedative effects of alcohol, leading to increased drowsiness and impairment.

Q: What are the main contraindications for Deanxit use?

Contraindications (reasons the drug must not be used) include recent heart attack, certain heart rhythm disorders, circulatory collapse, severe depression, and concomitant use with MAOIs (a specific class of antidepressant).

Q: Does Deanxit change appetite?

Yes, increased appetite is listed as an undesirable effect in official product information.

Q: Why do some official sources classify Deanxit as an antidepressant?

Official sources classify the medicine, in part, as an antidepressant because one of its active components, melitracen, belongs to the tricyclic antidepressant (TCA) class of medicines.

Q: What kind of studies support the combination of flupentixol and melitracen?

Official information and regulatory filings show that clinical studies have been conducted to evaluate the efficacy and safety of this specific combination in the treatment of emotional and depressive disorders.

Q: Can Deanxit be used for symptoms like fatigue or lack of energy?

Yes, Deanxit is officially indicated for the treatment of asthenia. Asthenia is a medical condition characterized by symptoms such as lack of energy, strength, and physical or mental weakness.

Q: Does Deanxit affect laboratory tests?

The drug may modify insulin and glucose responses and can affect the results of certain liver function tests (LFTs). Monitoring may be necessary for patients with related conditions.

Q: What information is available about Deanxit and eye pressure (glaucoma)?

The product information states that Deanxit is advised to be used with caution in patients with certain eye conditions, such as narrow-angle glaucoma. The official warning is due to the potential for pupillary dilation, which may provoke acute glaucoma attacks.

Q: Is there a patient leaflet (PIL) available for Deanxit online?

Yes, Patient Information Leaflets (PILs) for Deanxit are published by various government drug authorities in the regions where the medicine is approved and marketed.

Q: Can Deanxit cause dry mouth?

Yes, dry mouth is listed as one of the commonly reported undesirable effects in the official product information.

Q: What happens if a person takes too much Deanxit?

Official documents state that symptoms of overdose may include drowsiness, unconsciousness, fits/seizures, low or high blood pressure, and fast or irregular heart rate. The official guidance emphasizes that this constitutes a serious medical emergency.

Q: Does Deanxit affect heart rhythm?

Deanxit can affect heart rhythm; it is contraindicated in patients with certain disorders of cardiac rhythm. The medicine can cause effects such as tachycardia (fast heart rate) and prolonged QT interval.

Q: Is it described as normal for side effects to decrease over time?

Yes, official documents describe side effects as generally being most pronounced at the beginning of the treatment. Most of these effects usually wear off as the patient continues to take the medicine.

Q: What are the main safety warnings associated with Deanxit?

The main warnings noted in official documents include the risk of suicidal thoughts, caution for patients with advanced heart or liver disease, and the rare risk of developing Neuroleptic Malignant Syndrome (NMS).

Q: What happens if I stop taking Deanxit suddenly?

Official documents strongly recommend against stopping Deanxit suddenly. Abrupt discontinuation can increase the risk of experiencing severe adverse effects or withdrawal symptoms. Official guidance emphasizes that the dosage typically needs to be reduced gradually (tapered off) when treatment ends.

Q: Are there any specific foods or drinks that should be avoided while taking Deanxit?

Official product information advises against the consumption of alcohol while undergoing treatment with Deanxit, as the medicine may increase the sedative effects of alcohol. Regarding food, the tablets can generally be taken either with or without a meal.

Q: Is Deanxit suitable for use in elderly patients?

The official product information states that caution is advised when Deanxit is used in older adults (over 65 years). This is because the elderly may be more sensitive to the medicine's effects and potential side effects; due to this increased sensitivity, lower starting doses are often utilized.

Q: What evidence exists regarding the use of Deanxit in children or adolescents?

Regulatory documents state that Deanxit is generally not recommended for use in individuals under the age of 18. This position is based on a lack of adequate data regarding both the efficacy and the safety of the medicine in this younger population.

Q: What are the official recommendations for tapering off Deanxit?

Official recommendations emphasize that the dosage must be gradually decreased when discontinuing treatment. This tapering process is advised to help prevent potential withdrawal symptoms or the return of underlying conditions.

Q: What is the relevance of the fixed dose combination of the two active ingredients?

The relevance of this fixed-dose combination lies in its dual mechanism of action. It combines melitracen (an antidepressant component) with a low dose of flupentixol (a neuroleptic component) to target symptoms of mild-to-moderate depression, anxiety, and lack of energy simultaneously.

Q: What are the specific components of Deanxit and their pharmacological class?

The medicine contains two active ingredients: melitracen and flupentixol. Regulatory classifications describe melitracen as a tricyclic antidepressant (TCA) and flupentixol as a neuroleptic, specifically a thioxanthene derivative.

How to Store and Dispose of Deanxit?

Deanxit film-coated tablets must be stored according to regulatory requirements to ensure drug stability. The official storage condition mandates keeping the medication below 30°C.

Storage Requirements

The product must be kept in its original container and protected from environmental factors that cause degradation, specifically light, heat, and moisture. A mandatory safety rule requires that Deanxit be stored out of the reach and out of the sight of children at all times.

Constraint	Requirement
Temperature	Store below 30 C
Protection	Protect from heat, light, and moisture

Disposal Instructions

Disposal of unused or expired tablets should follow official guidelines. The preferred method is using a community drug take-back program. If this is unavailable, the medication must be removed from its container, mixed with an undesirable substance (e.g., dirt, coffee grounds), sealed in a bag, and then placed in the household trash. The empty container must have all personal information obscured before disposal.